Plasma Asprosin Concentrations are Associated with Progression of Diabetic Kidney Disease.

asprosin diabetes diabetic kidney disease kidney injury

Journal

Diabetes, metabolic syndrome and obesity : targets and therapy
ISSN: 1178-7007
Titre abrégé: Diabetes Metab Syndr Obes
Pays: New Zealand
ID NLM: 101515585

Informations de publication

Date de publication:
2024
Historique:
received: 20 11 2023
accepted: 09 05 2024
medline: 10 6 2024
pubmed: 10 6 2024
entrez: 10 6 2024
Statut: epublish

Résumé

To explore the expression of asprosin in subjects with pre-DKD and DKD and to analyze its relationship with kidney injury, inflammation, and glucose and lipid metabolism. Based on urine albumin:creatinine ratio (UACr), participants were divided into DM, pre-DKD, and DKD groups. Relevant human physiological and biochemical parameters were detected in the three groups. We found relatively higher levels of asprosin in both pre-DKD and DKD groups than the DM group. Moreover, data from the Nephroseq database support increased gene expression of asprosin in kidney tissue from DKD patients. Further correlation analysis revealed that the plasma asprosin level was positively correlated with age, waist circumference, waist:hip ratio, systolic blood pressure, creatinine, UACr, triglycerides, HDL-c, fasting insulin, HOMA-IR, and the inflammatory marker G3P and negatively associated with eGFR. Multiple logistical regression analysis showed that asprosin concentration was significantly associated with pre-DKD and DKD after adjusting for sex, age, BMI, WHR, and HOMA-IR, while this correlation was lost after controlling for G3P. Plasma asprosin is associated with kidney injury in diabetic conditions, and this association might be connected through inflammatory response. Further studies are needed to assess the role and mechanism of asprosin in DKD.

Identifiants

pubmed: 38854448
doi: 10.2147/DMSO.S447465
pii: 447465
pmc: PMC11162641
doi:

Types de publication

Journal Article

Langues

eng

Pagination

2235-2242

Informations de copyright

© 2024 Xu et al.

Déclaration de conflit d'intérêts

The authors declare that there are no conflicts of interest in this work.

Auteurs

Mingyue Xu (M)

Department of Endocrinology, Translational Research of Diabetes Key Laboratory of Chongqing Education Commission of China, Second Affiliated Hospital of Army Medical University, Chongqing, People's Republic of China.

Chunlin Zhang (C)

Department of Endocrinology, Translational Research of Diabetes Key Laboratory of Chongqing Education Commission of China, Second Affiliated Hospital of Army Medical University, Chongqing, People's Republic of China.

Linlin Zhang (L)

Department of Endocrinology, Translational Research of Diabetes Key Laboratory of Chongqing Education Commission of China, Second Affiliated Hospital of Army Medical University, Chongqing, People's Republic of China.

Hua Qu (H)

Department of Endocrinology, Translational Research of Diabetes Key Laboratory of Chongqing Education Commission of China, Second Affiliated Hospital of Army Medical University, Chongqing, People's Republic of China.

Yuren Wang (Y)

Department of Endocrinology, Translational Research of Diabetes Key Laboratory of Chongqing Education Commission of China, Second Affiliated Hospital of Army Medical University, Chongqing, People's Republic of China.

Classifications MeSH